Categories Earnings, Other Industries

Flexion Therapeutics plunges after reporting preliminary Q4 financial results

Flexion Therapeutics (Nasdaq: FLXN) reported its preliminary fourth quarter earnings results after the bell today. The biopharmaceutical company’s Q4 revenue is expected to be approximately $9.5 million, representing a 36% increase over the prior year quarter. Full-year 2018 revenue is estimated to be about $22.5 million. Shares of Flexion tanked more than 10% in the extending trading hours.

Flexion anticipates 2019 ZILRETTA product revenue to be in the range of $65 million to $80 million. The company will report complete financial results for Q4 and FY18 later in the first quarter. Flexion plans to discuss the preliminary results in a conference call that is scheduled for Friday, January 4 at 8:30 AM ET.

“2018 was a foundational year for ZILRETTA, and in the first full year of the launch, we saw strong product uptake as we established a broad and growing base of prescribers. Furthermore, the clinical feedback on ZILRETTA from physicians and patients alike continues to be overwhelmingly positive and gratifying,” said Michael Clayman, CEO.

On Wednesday, the Burlington, Massachusetts-based biotech company announced that it enrolled the first patient in the Phase 3 trial of ZILRETTA in late December 2018. This hip osteoarthritis trial is expected to be completed in the year 2020. Flexion also plans to initiate additional Phase 2 studies of ZILRETTA in the shoulder later this year.

Bristol-Myers Squibb swallows Celgene for $74-bln; Celgene stock surges

Flexion stock, which plunged to a yearly low ($11.14) on December 24, 2018, had dropped 52% in the past year. The stock ended Thursday’s trading session down 1,04% at $12.33 and is expected to hit a new 52-week low tomorrow as the preliminary results disappointed the investors.

Also Read:  China growth slump pulls down oil prices


We’re on Apple News! Follow us to receive the latest stock market, earnings, and financial news at your fingertips



Most Popular

Chewy (CHWY) stock drops after reporting Q4 earnings; FY20 forecast not given

Online pet food seller Chewy Inc.'s (NYSE: CHWY) bottom line beat the market's estimates, while sales met the targets in the fourth quarter of 2019. The company posted a loss

Ford (F) got hit by COVID-19 and here’s why a recovery will not be easy

Ford Motor Company (NYSE: F) reported a 12.5% decline in total US vehicle sales for the first quarter of 2020. The sales numbers were heavily impacted by the coronavirus outbreak

US unemployment claims double to 6.6 million in a week; stocks fall

After climbing to a record high a week ago, jobless claims in the US more than doubled and reached unprecedented levels in the week ended March 28 as more and